


Cardiovascular Disease & Heart Health VC Market Snapshot

2023





Contents

Introduction	3
Cardiovascular disease & heart health VC ecosystem market map	5
VC activity	7
Opportunities	11
Risks and considerations	16
Market segmentation	17

Institutional Research Group

Analysis



Aaron DeGagne, CFA Analyst, Emerging Technology
aaron.degagne@pitchbook.com



Kazi Helal, Ph.D. Senior Analyst, Emerging Technology
kazi.helal@pitchbook.com



Rebecca Springer, Ph.D. Lead Analyst, Healthcare
rebecca.springer@pitchbook.com



Ben Riccio Emerging Technology Intern

Data

Collin Anderson Data Analyst
pbinstitutionalresearch@pitchbook.com

Publishing

Report designed by **Chloe Ladwig**

Published on September 7, 2023



Introduction

Cardiovascular disease is the leading cause of death both globally and in the US. Each year it accounts for about 12% of total US healthcare expenditure.¹ Incidence of cardiovascular disease, including hypertension, vascular disease, and heart failure, increases with age. In 2019, there were 54 million people aged 65 and older in the US, 18% of which reported having at least one cardiovascular condition;² this age group is expected to grow to over 80 million people by 2040. Obesity is also a key contributor to cardiovascular disease, and a new class of GLP-1 weight loss drugs that appear to not only enable significant weight loss, but also reduce adverse cardiovascular events, is poised to significantly disrupt the cardiovascular care and technology industry.

These trends present a widespread need and growing opportunity for innovative cardiovascular diagnostics, treatments, and digital care solutions. As a result, cardiovascular disease & heart health startups have raised over \$20 billion in VC funding since 2020. We segment VC-backed cardiovascular disease & heart health into the following categories: patient monitoring, devices & implants, cardiac imaging, chronic condition management & prevention, and biopharmaceuticals.


Market size

We estimate the market size for cardiovascular care solutions at over \$300 billion, including care delivery, cardiac devices, chronic condition management, patient monitoring, and other digital solutions. Demographic drivers previously discussed could bring the total direct cost of cardiovascular care up to \$400 billion by 2030, assuming a conservative compound annual growth

1: "Heart Disease and Stroke Statistics—2023 Update: A Report from the American Heart Association," American Heart Association, Connie W. Tsao, et al., February 21, 2023.

2: "Health, United States 2020-2021," CDC, June 26, 2023.

Cardiovascular disease & heart health market size estimate (\$B)



Source: PitchBook • Geography: Global • *As of August 8, 2023



INTRODUCTION

rate of 4.0%. While technological innovation and the shift to value-based care may eventually slow down growth of healthcare spending, the rising incidence of cardiovascular disease is likely to drive cardiovascular costs upward for the foreseeable future.

Beyond the current market potential, rapid adoption of weight loss drugs could significantly disrupt cardiovascular care, given the established relationship between weight and cardiovascular risk factors. The weight loss drug market is potentially massive, with over 40% of all Americans classified as medically obese.³ If these drugs become a realistic solution for a fraction of the obese American population, the market size for weight loss therapeutics could reach or exceed current market estimates of \$100 billion.⁴ While the long-term impact on cardiovascular care is uncertain, these drugs have potential to significantly reduce spending on other areas of cardiovascular disease & heart health, reducing the incidence of both acute cardiac events and related chronic conditions.

³: ["Adult Obesity Facts," CDC, May 17, 2022.](#)


⁴: ["Obesity Could Be Pharma's Biggest Blockbuster Yet," The Wall Street Journal, David Wainer, May 5, 2023.](#)



Cardiovascular disease & heart health VC ecosystem market map

Click to view the interactive market map on the PitchBook Platform.

Market map is a representative overview of venture-backed or growth-stage providers in each segment. Companies listed have received venture capital or other notable private investments.





Cardiovascular disease & heart health VC ecosystem market map

Click to view the interactive market map on the PitchBook Platform.

Market map is a representative overview of venture-backed or growth-stage providers in each segment. Companies listed have received venture capital or other notable private investments.






VC activity

In 2020, 2021, and 2022, cardiovascular disease & heart health companies raised at least \$3.5 billion in VC capital annually, reaching a peak of \$5.3 billion in 2021. Fundraising by cardiovascular care startups has followed the larger healthcare and overall VC funding environment, with sharp declines in total deal value and deal count since 2021. However, YTD deal activity is on pace to roughly match the \$3.5 billion recorded in 2022. Additionally, despite fundraising headwinds, especially for late-stage companies, 10 cardiovascular disease & heart health startups closed rounds over \$100.0 million in the past two years. Five of these were biopharmaceutical companies, including [Cardurion Pharma](#), which raised \$300.0 million in July 2023 to develop molecular inhibitors that treat heart failure and other cardiovascular diseases; and [Rivus Pharmaceuticals](#), which raised \$132.0 million in August 2022 for a metabolic accelerator drug to treat obesity and heart failure. Analysis of PitchBook's clinical trials data shows that the majority of VC funding in this segment has flowed into companies with their most advanced cardiovascular product in Phase 2 trials.


The cardiovascular imaging segment has also attracted significant investor interest over the past two years. Computerized tomography (CT) imaging companies [Heartflow](#) and [Cleerly](#) posted \$215.0 million and \$192.0 million rounds in March 2023 and July 2022, respectively, while [CathWorks](#) took in a \$75.0 million investment from [Medtronic](#) as part of a \$585 million option-to-acquire agreement. These large deals brought total fundraising for cardiovascular imaging companies over 2021's figure in both 2022 and 2023, and highlight growing investor interest in artificial intelligence and machine learning (AI & ML) applications for cardiovascular care.

Cardiovascular disease & heart health VC deal activity



Source: PitchBook • Geography: Global • *As of August 8, 2023

Cardiovascular disease & heart health VC exit activity




Source: PitchBook • Geography: Global • *As of August 8, 2023



VC ACTIVITY


The cardiovascular disease & heart health market saw a wave of exits in 2021, including 12 IPOs. In line with the broader VC asset class, the cardiovascular space has seen exits decline sharply from that peak, with only five exits completed YTD. Since 2020, biopharmaceuticals and devices & implants have dominated exit activity, with 17 of the largest 20 exits coming from these segments. These include [Bayer's](#) \$3.9 billion acquisition of [AskBio](#), a clinical-stage gene therapy company treating heart failure and non-cardiovascular diseases, in 2020; after 2021, [Medtronic](#) was responsible for two of the largest exits, acquiring atrial fibrillation device company [Affera](#) and CT scan analysis platform [CathWorks](#) in 2022; additionally, [CinCor Pharma](#) went public in 2022 before being acquired by [AstraZeneca](#) the following year; and [Mineralys](#) went public in January 2023.

Cardiovascular disease & heart health VC deal activity by quarter



Source: PitchBook • Geography: Global • *As of August 8, 2023

Cardiovascular disease & heart health VC exit count by type




Source: PitchBook • Geography: Global • *As of August 8, 2023




VC ACTIVITY

Cardiovascular biopharmaceuticals VC deal volume by lead cardiovascular candidate phase (\$M)



Source: PitchBook • Geography: Global • *As of August 8, 2023

VC deal count by phase and segment for active cardiovascular trials sponsored by VC-backed companies*



Source: PitchBook • Geography: Global • *As of August 8, 2023



VC ACTIVITY

Key VC deals YTD by deal value (\$M)*

Company	Close date	Category	Deal value (\$M)	Pre-money valuation (\$M)	Lead investor(s)	Most advanced active cardiovascular trial phase
Cardurion Pharma	July 12, 2023	Heart failure	\$300.0	\$210.0	N/A	Phase 2
HeartFlow	March 2, 2023	Cardiac CT	\$215.0	N/A	Bain Capital	N/A
Cleerly	July 25, 2022	Cardiac CT	\$192.0	\$408.0	Fidelity Management & Research, T. Rowe Price	N/A
Omada	February 23, 2022	Hypertension management & weight loss	\$192.0	\$840.0	Fidelity Management & Research	N/A
Sinotau	July 3, 2023	Stroke & heart attack	\$153.4	N/A	N/A	N/A
AliveCor	August 16, 2022	Remote ECG monitoring	\$150.0	\$830.0	GE Healthcare	N/A
Rivus Pharmaceuticals	August 19, 2022	Weight loss	\$132.0	\$300.0	RA Capital Management	Phase 2
Mineralys	June 1, 2022	Antihypertensives & cholesterol lowering	\$118.0	\$150.0	Andera Partners, RA Capital Management	Phase 2
Impulse Dynamics	May 23, 2022	Heart failure	\$101.0	N/A	N/A	N/A
TrueBinding	June 16, 2022	Stroke & heart attack	\$100.0	\$82.0	N/A	Phase 2

Source: PitchBook • Geography: Global • *As of August 8, 2023



Opportunities

Remote patient monitoring (RPM): Even before the pandemic-fueled telehealth boom, cardiology was one of the first specialties to take advantage of RPM, mostly in the form of implants and home blood pressure monitors. The specialty is well suited to RPM because conditions like weight management and hypertension require daily measurements to track progress and assess risk, while others, such as arrhythmias, occur intermittently and may not be recorded during an in-clinic test. Electrocardiogram (ECG) monitoring in particular has shifted toward remote care by transforming bulky wearables with plugs and leads to small patches or at-home devices that can record large amounts of accurate data. [AliveCor](#) is the VC-backed leader in this space, raising \$150.0 million in 2022 for their credit-card sized medical-grade ECG devices. The RPM space also benefits from favorable reimbursement dynamics. The Centers for Medicare and Medicaid Services (CMS) overhauled Medicare RPM codes—which cover not only the devices themselves, but device setup, patient education, and monitoring time—in 2018 and has been gradually expanding coverage for RPM since then.⁵

As RPM and at-home-care technology becomes more popular, there is also an increased demand for efficient ways to aggregate and analyze data collected by these devices. Providers may use multiple wearable monitoring devices that track patients for hours or days, collecting vast amounts of data. We believe the long-term reimbursement dynamic for RPM will turn on the extent to which providers actually make use of the resulting data in order to deliver (and measure) meaningfully better patient outcomes. This will require software that organizes RPM data within the electronic health record and enhances both interpretation and actionability. Companies developing RPM software include [Murj](#) and [Implicitly](#), which raised \$113.9 million and \$22.4 million rounds in 2022, respectively.

5: “Medicare Remote Patient Monitoring Reimbursement FAQs: Everything You Need to Know About Chronic Care Remote Physiologic Monitoring Codes,” [Foley, Nathaniel M. Lactman, November 2, 2018.](#)

Digital hypertension management and weight loss solutions: Over 1.2 billion people globally suffer from hypertension, or high blood pressure,⁶ and obesity is the primary cause for an estimated 65% of all hypertension cases.⁷ There is an emerging opportunity to address this large patient group using digital care programs. Weight loss programs offered by companies like [Noom](#), which raised \$668.8 million in 2023, provide personalized coaching, nutritional guidance, monitoring technology, and prescriptions for weight loss drugs. Other companies offer similar features with a greater focus on hypertension. [Hello Heart](#), which raised \$70.0 million in 2022, also offers coaching but provides more comprehensive blood pressure monitoring and easy access to physicians.

Both types of programs typically offer their solutions either directly to consumers or through partnerships with health plans and/or employers. Weight loss drug prescriptions will become both a key revenue source and go-to-market strategy for these providers as commercial plans and self-insured employers expand coverage in the coming years. Some plans and employers will prefer to offer medications as part of a more holistic approach to supporting heart health through diet and exercise, and digital providers will differentiate themselves by offering comprehensive solutions and earning higher patient engagement. Some programs also operate on a B2B2C model, relying on providers for patient referrals. These digital solutions can enhance traditional treatment plans by offering personalized care outside of a clinical setting.

Surgical technology expanding cardiac outpatient care options: Advancements in surgical technology are allowing cardiovascular procedures that previously required hospitalization to be safely performed in ambulatory settings. In 2020 and 2021, CMS added 17 cardiac-related

6: “Hypertension,” [World Health Organization, March 16, 2023.](#)

7: “Obesity-Related Hypertension: A Review of Pathophysiology, Management, and the Role of Metabolic Surgery,” [National Library of Medicine, Omair A. Shariq and Travis J. McKenzie, February 2020.](#)



OPPORTUNITIES

Select VC-backed cardiovascular CT imaging startups*

Company	HQ location	Total raised (\$M)	Last financing deal type	Last financing round (\$M)	Lead investor
HeartFlow	Mountain View, CA	\$828.8	Series F	\$215.0	Bain Capital
Cleerly	New York, NY	\$266.3	Series C	\$192.0	Fidelity Management & Research, T. Rowe Price
Elucid	Boston, MA	\$56.8	Late-stage VC	\$11.0	Philips Health Technology Venture Fund
Caristo Diagnostics	Oxford, UK	\$30.1	Series A	\$15.8	Oxford Science Enterprises
Medipixel	Seoul, South Korea	\$9.9	Series A	\$8.6	Mirae Asset Capital
Inheart	Pessac, France	\$4.3	Series A	\$4.3	Elaia Partners
IMedis	Rehovot, Israel	\$3.7	Grant	\$1.8	N/A
Nurea	Bègles, France	\$1.6	Early-stage VC	\$1.1	Technostart, Paris Business Angels, Bpifrance

Source: PitchBook ▪ Geography: Global ▪ *As of August 8, 2023



OPPORTUNITIES

procedures to the Ambulatory Surgical Center (ASC) coverage list, doubling the previous total.⁸ These included mostly catheter-based procedures for diagnostics, angioplasties, stent implantation, and other percutaneous coronary interventions. More codes are expected to be added in the future, including electrophysiology (EP) ablations and transcatheter aortic valve replacements. As payers and PE-backed consolidators seek to push cardiovascular care into lower-cost ASCs and outpatient-based laboratories, demand for technologies that enable minimally invasive surgeries and efficient, cost-effective care will increase—although traditional hospital buyers of cardiovascular devices will be financially weakened. For example, [Medtronic](#) acquired EP mapping and ablation company [Affera](#) for \$904.0 million in 2022, expanding its cardiovascular ablation portfolio to meet demand for safer atrial fibrillation treatment techniques.

AI image analysis for vascular disease treatment: There is a large market opportunity for early detection of vascular disease, particularly atherosclerosis, or plaque buildup in arteries. Atherosclerosis narrows arteries and restricts blood flow, causing heart attack and stroke. AI-powered software that can locate plaque buildups before they cause a serious cardiac event enable early detection for patients with vascular disease and reduce diagnostic errors. Companies like [Elucid](#), which raised \$22.0 million in 2022, analyze CT images to produce 3D models of patients' arteries. These models help physicians target plaque buildup for stent implantation or angioplasty.

Next-generation treatments: Driven by growing demand and scientific advancements, the weight loss drug market is ripe with opportunity. With market estimates for the next decade exceeding \$100 billion, the return potential for those venturing into this category is robust. This financial

promise is buoyed by a shift in the scientific understanding of obesity. No longer just viewed as the consequence of lifestyle choices, obesity's recognition as a chronic disease has paved the way for novel treatments. GLP-1 antagonists, which have shown promising early results, are a testament to this shift.

In the longer term, emerging drug modalities such as gene therapy may provide a one-time treatment or "cure" for obesity as well as other cardiovascular conditions. Although most forms of cardiovascular disease are difficult candidates for gene therapies—since they are caused by numerous genetic and lifestyle factors—rare cardiovascular diseases represent more attractive genetic medicine targets. For example, [Lexeo Therapeutics](#), which raised \$100 million in 2021, is in combined Phase 1/Phase 2 clinical trials for a gene additive approach for Friedreich's Ataxia induced cardiomyopathy, a rare disorder typically caused by a single genetic mutation. Another gene therapy example but for wider use, [Cardior](#), raised \$75.0 million in 2021 and is developing RNA technology to prevent cardiac muscle changes induced by heart attacks. This technology would be applicable to a significant population, as 20% to 30% of heart attack survivors later develop heart failure.⁹

Advancements in the science, alongside AI & ML drug discovery and precision medicine methods, may also lead to significant improvements in treatment via newly engineered peptides or small molecules. Extensive media attention to current GLP-1 antagonist products heightens awareness and may lead to accelerated adoption of alternatives when they become available.

8: "ASC: Same Day Surgery for Cardiovascular Care," *Atlantis Worldwide*, Vikki Harmonay, May 19, 2021.

9: "Heart Failure After Myocardial Infarction: Incidence and Predictors," *National Library of Medicine*, Dominik Jenča, et al., February 2021.



OPPORTUNITIES

Finally, there is a discernible opportunity for drug developers to carve out niches beyond obesity and diabetes if their medications offer multifaceted benefits. For instance, drugs that not only promote weight loss but also mitigate other obesity-related health complications are more likely to receive payer coverage. [Novo Nordisk](#)'s Wegovy medication has not only proven its weight loss efficacy but has also demonstrated a 20% reduction in major adverse cardiovascular events in obese patients.¹⁰

¹⁰: ["Updated: Novo Nordisk's Semaglutide Injection Reduces Cardiovascular Events By 20% In Vast SELECT Trial," Endpoints News, Katherine Lewin, August 8, 2023.](#)



OPPORTUNITIES

Noteworthy VC deals and exits for clinical-stage companies with clinical-stage gene therapies for cardiovascular disease*

Company	Deal type	Close date	Deal value (\$M)	Pre-money valuation (\$M)	Lead investor(s)/acquirer(s)	Cardiovascular condition(s)	Most advanced active cardiovascular trial phase
XyloCor Therapeutics	Late-stage VC	December 14, 2022	\$412.0	\$62.6	Fountain Healthcare Partners	Coronary Artery Disease	Phase 1/2
Lexeo Therapeutics	Early-stage VC	September 9, 2021	\$100.0	\$250.0	D1 Capital Partners, Eventide Asset Management	Cardiomyopathy, Cardiac Friedrich's Ataxia	Phase 1/2
Cardior	Late-stage VC	August 25, 2021	\$75.4	N/A	Inkef	Heart failure	Phase 2
Tenaya Therapeutics	IPO	July 30, 2021	\$180.0	\$589.9	N/A	Cardiomyopathy	Phase 1
Verve Therapeutics	IPO	June 17, 2021	\$266.7	\$876.1	N/A	Hypercholesterolemia	Phase 1
4DMT	IPO	December 11, 2020	\$193.2	\$580.4	N/A	Farby disease	Phase 1/2
AskBio	M&A	December 1, 2020	\$3,861.4	\$3,861.4	Bayer	Heart failure	Phase 2

Source: PitchBook • Geography: Global • *As of August 8, 2023



Risks and considerations

Commercialization challenges of weight loss drugs: The promise of novel weight loss drugs is tempered by significant commercialization challenges. The current dominant position of incumbents, chiefly [Novo Nordisk](#) and [Eli Lilly](#), may make it difficult for startups to carve out a significant market share. Moreover, adoption of the current crop of weight loss drugs may be slowed for the next one to two years by a lack of coverage by commercial payers and self-insured employers, who could potentially face enormous short-term costs without fully reaping the longer-term benefits of reducing cardiovascular disease and related conditions. Additionally, a 2003 Medicare law disallows coverage for weight loss drugs. The ultimate fate of VC-backed challengers in the weight loss drug arena may hinge on how successful “first wave” manufacturers are at proving their products significantly reduce patients’ overall health outcomes, thereby paving the way for favorable coverage decisions. One worthwhile avenue may be to start with international markets to prove population-level efficacy; Wegovy will soon be available to treat obesity via the National Health Service at the cost of \$88 per month, compared with a list price of \$1,349 in the US.

Point solution fatigue: We track nearly 500 companies in our database of VC-backed cardiovascular disease & heart health startups, and many patient-facing categories in cardiology such as personal monitoring, general heart health, and chronic condition management are saturated with startups offering limited differentiation. The issue of fragmentation is particularly acute in the employer-facing market, given that there is little need for employers to have a wide

variety of similar solutions, especially in an environment where new benefit costs are being scrutinized for engagement and cost-effectiveness. 43% of employers believe there are too many digital health solutions on the market.¹¹ Heart health startups also face the “chicken and egg” problem of needing long-term data to support claims of cost reduction but often receiving limited interest in their solution without being able to offer supporting data.

Consumer wearables: Remote monitoring device startups face competition from consumer wearable companies beginning to expand their cardiac coverage. In 2022, the Food and Drug Administration approved the [Apple](#) Watch’s “AFib History” feature, which uses a built-in ECG to alert users to signs of atrial fibrillation, and a similar feature was approved for FitBit, [Google’s](#) popular fitness tracker. If widely-used consumer wearables can add comprehensive heart health to their long list of features, companies developing cardiovascular-focused consumer devices may have difficulty attracting customers to pay a premium for medical-grade solutions.

¹¹: “Employers’ Enthusiasm for Virtual Care Is On The Decline: Business Group,” Fierce Healthcare, Paige Minemyer, August 22, 2023.



Market segmentation

Patient monitoring

Patient monitoring companies offer devices and software that collect or analyze patient data. This segment includes wearable or portable devices that allow for at-home monitoring, as well as point-of-care examination tools and tests, and any provider-used software that analyzes patient data gathered from these devices.

RPM is a large part of this segment, as it allows patients to monitor their heart health or record rare cardiac arrhythmias that may not occur during a short clinical examination. As more patient data becomes available, there is an increased opportunity for software capable of analyzing it. Companies employing AI or machine learning to aid in diagnostics can provide quick and detailed insights into patient health.

- **Digital stethoscopes:** Devices that replace traditional stethoscopes by allowing physicians to listen to and record heart sounds.
- **General heart health:** Devices that record a patient's heart rate, blood pressure, blood oxygen, and other vital signs to provide insights into overall heart health.
- **Hemodynamic monitoring:** Devices or equipment that monitor blood flow and/or heart pump performance.
- **Other monitoring:** Other devices or equipment for monitoring cardiovascular health.
- **Patient data analysis:** Software that manages patient data from monitoring devices to enable risk analysis, triage, diagnosis, or treatment planning.
- **Perinatal monitoring:** Devices or equipment that monitor fetus or newborn heart health.
- **Remote ECG monitoring:** Portable or wearable ECG devices that allow patients to record electrical activity of the heart outside of a clinic.

- **Risk management & diagnostics:** Tests or diagnostic tools that examine patient biomarkers to assess risk or diagnose heart conditions.

Devices & implants

This segment includes companies that provide physical solutions to aid in the treatment of a variety of cardiovascular conditions. This includes implants like stents, pacemakers, and heart valve aids, as well as tools for catheter-based interventions like ablations and angioplasties. These devices often address structural heart defects or restore blood flow through arteries or veins.

- **Cardiac arrhythmias:** Devices or implants that prevent or treat irregular heartbeat patterns like atrial fibrillation.
- **Heart failure:** Devices or implants that compensate or completely take over blood pumping functions of the heart.
- **Vascular disease:** Devices or implants that increase blood flow by expanding or clearing blocked blood vessels.
- **Heart valve:** Devices or implants that address defective heart valves.
- **Manufacturing & distribution:** Companies that manufacture or distribute a variety of cardiac devices and implants.
- **Other devices or implants:** Other tools and technology that address cardiac conditions.

Cardiovascular imaging

Cardiovascular imaging companies offer devices and software to generate images or models of the cardiovascular system. In this segment we include traditional imaging devices such as



MARKET SEGMENTATION

echocardiographs, CT scanners, and cardiac magnetic resonance image (MRI) machines, as well as software designed to analyze diagnostic images. Many of these software solutions employ AI or machine learning to develop models of a patient's cardiovascular system or aid in diagnosis.

- **Cardiovascular CT:** Equipment or software that produces or analyzes computerized tomography scans, including coronary angiograms.
- **MRI:** Equipment or software that produces or analyzes cardiovascular MRIs.
- **Echocardiogram:** Equipment or software that utilizes ultrasound for cardiovascular imaging.
- **Other imaging:** Other equipment for producing images of the cardiovascular system.

Chronic condition management & prevention:

The chronic condition management & prevention segment includes companies that offer digital solutions or devices that support patients and their physicians in monitoring heart health and managing chronic cardiovascular conditions. In this segment, we include digital programs for cardiac rehabilitation, hypertension management, weight loss, and other chronic conditions. Additionally, we include consumer devices designed to allow anyone to monitor their heart health.

- **Cardiac rehabilitation:** Digital programs designed for patients who have recently experienced an acute cardiac event or undergone a significant intervention. These programs provide coaching, monitoring technology, education, and other telehealth services to promote cardiac recovery.

- **Hypertension management & weight loss:** Digital programs intended to help people manage high blood pressure or weight loss. These programs offer coaching, monitoring, and access to physicians.
- **Consumer heart monitoring:** Consumer devices that track users' heart rate, blood pressure, heart rate variability, and other vitals for the purpose of gaining insights into overall cardiac health.
- **Other chronic condition management:** Other digital solutions that coordinate or provide care to patients with cardiovascular disease.


Biopharmaceuticals

Companies in this segment offer therapeutic solutions to patients suffering from cardiovascular diseases and associated risk factors. This includes drugs that lower high blood pressure or cholesterol, increase the heart's ability to pump blood, and address strokes. Additionally, weight loss drugs are included. While the weight loss drug space is currently dominated by large, public, pharmaceutical companies, there are a few VC-backed companies developing potentially competitive products.



MARKET SEGMENTATION

- **Gene therapies:** Technologies that treat a variety of cardiovascular conditions using genetic methods.
- **Antihypertensives & cholesterol reducers:** Therapeutics that lower blood pressure or cholesterol levels.
- **Heart failure:** Therapeutics that improve heart function by regenerating cardiac tissue, modulating contraction strength and speed, and other methods.
- **Stroke & heart attack:** Therapeutics for patients suffering from a stroke or heart attack. This includes preventative treatments like blood thinners and antiplatelet drugs, as well as drugs that promote recovery via tissue regeneration, anti-inflammation, or other methods.
- **Weight loss:** Drugs that promote weight loss or aid in weight management.
- **Arrhythmias, artery disease & other conditions:** Therapeutics that treat other cardiovascular conditions, such as arrhythmias, artery disease, or rare cardiovascular diseases.



About PitchBook Industry and Technology Research

Independent, objective, and timely market intel

As the private markets continue to grow in complexity and competition, it's essential for investors to understand the industries, sectors and companies driving the asset class.

Our Industry and Technology Research provides detailed analysis of nascent tech sectors so you can better navigate the changing markets you operate in—and pursue new opportunities with confidence.

©2023 by PitchBook Data, Inc. All rights reserved. No part of this publication may be reproduced in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, and information storage and retrieval systems—without the express written permission of PitchBook Data, Inc. Contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Nothing herein should be construed as any past, current or future recommendation to buy or sell any security or an offer to sell, or a solicitation of an offer to buy any security. This material does not purport to contain all of the information that a prospective investor may wish to consider and is not to be relied upon as such or used in substitution for the exercise of independent judgment.

PitchBook Data, Inc.

John Gabbert Founder, CEO

Nizar Tarhuni Vice President, Institutional Research and Editorial

Paul Condra Head of Emerging Technology Research

Additional research

Eric Bellomo
eric.bellomo@pitchbook.com
Gaming
E-Commerce

Brendan Burke
brendan.burke@pitchbook.com
Internet of Things
Information Security
Artificial Intelligence & Machine Learning

Aaron DeGagne
aaron.degagne@pitchbook.com
Medtech
Digital Health

Alex Frederick
alex.frederick@pitchbook.com
Agtech
Foodtech

Jonathan Geurkink
jonathan.geurkink@pitchbook.com
Supply Chain Tech
Mobility Tech

Kazi Helal
kazi.helal@pitchbook.com
Biopharma
Pharmatech

Derek Hernandez
derek.hernandez@pitchbook.com
Enterprise SaaS

Ali Javaheri
ali.javaheri@pitchbook.com
Emerging Spaces

Robert Le
robert.le@pitchbook.com
Insurtech
Crypto

John MacDonagh
john.macdonagh@pitchbook.com
Carbon & Emissions Tech
Clean Energy Tech

Rebecca Springer
rebecca.springer@pitchbook.com
Healthcare Services
Healthcare IT

Rudy Yang
rudy.yang@pitchbook.com
Enterprise Fintech
Retail Fintech